SCHEMBL3490134

SCHEMBL3490134

CN1CCN(c2cc(Cl)cc3c2S(=O)(=O)N(CCc2ccccc2)C(=O)N3Cc2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
ALDH1A1 P00352 1/20 0.47
PABPC1 P11940 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPK1 P28482 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.46
ADRA1D P25100 7/20 0.44
ADRA1A P35348 7/20 0.44
ADRA1B P35368 7/20 0.44
HRH4 Q9H3N8 1/20 0.40
SIGMAR1 Q99720 1/20 0.39
EGFR P00533 2/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490278 0.93 MAPT (0.48) MAPTALDH1A1PABPC1RAB9ASMN1; SMN2
SCHEMBL3489620 0.92 MAPT (0.46) MAPTALDH1A1PABPC1RAB9ASMN1; SMN2
SCHEMBL3490206 0.91 MAPT (0.46) MAPTALDH1A1PABPC1RAB9ASMN1; SMN2
SCHEMBL3488615 0.90 MAPT (0.44) MAPTALDH1A1PABPC1RAB9ASMN1; SMN2
SCHEMBL3489623 0.90 MAPT (0.46) MAPTALDH1A1PABPC1RAB9ASMN1; SMN2
SCHEMBL3489081 0.88 MAPT (0.43) MAPTALDH1A1PABPC1RAB9ASMN1; SMN2
SCHEMBL3488912 0.88 MAPT (0.43) MAPTALDH1A1PABPC1RAB9ASMN1; SMN2
SCHEMBL3490480 0.88 MAPT (0.47) MAPTALDH1A1SMN1; SMN2MAPK1KDM4E
SCHEMBL3490501 0.88 MAPT (0.44) MAPTALDH1A1PABPC1RAB9ASMN1; SMN2
SCHEMBL3491691 0.88 MAPT (0.41) MAPTALDH1A1PABPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US claimed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D MAPT 2158/4885ALDH1A1 2748/4885PABPC1 3845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.